Date: 2012-10-30
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Vivalis (France) undisclosed large, international animal health firm
Therapeutic area: Veterinary medicine
Type agreement: licensing
Action mechanism:
Disease:
Details: Vivalis has signed a new EB66® research license with a large, international animal health firm. The license allows for the assessment of up to six different viruses in EB66®cells. To date, this is the second EB66® license agreement signed with this company.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
